Grace & White Inc. NY Has $12.41 Million Stake in West Pharmaceutical Services, Inc. (NYSE:WST)

Grace & White Inc. NY trimmed its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 4.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,330 shares of the medical instruments supplier’s stock after selling 1,880 shares during the quarter. West Pharmaceutical Services makes up about 2.2% of Grace & White Inc. NY’s investment portfolio, making the stock its 13th largest holding. Grace & White Inc. NY owned approximately 0.06% of West Pharmaceutical Services worth $12,406,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Whittier Trust Co. of Nevada Inc. lifted its holdings in West Pharmaceutical Services by 3.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 21,331 shares of the medical instruments supplier’s stock worth $6,402,000 after purchasing an additional 761 shares during the last quarter. Whittier Trust Co. lifted its holdings in West Pharmaceutical Services by 4.4% in the 3rd quarter. Whittier Trust Co. now owns 41,804 shares of the medical instruments supplier’s stock worth $12,547,000 after purchasing an additional 1,779 shares during the last quarter. Northwest Investment Counselors LLC acquired a new stake in West Pharmaceutical Services in the 3rd quarter worth approximately $30,000. Vest Financial LLC lifted its holdings in West Pharmaceutical Services by 31.0% in the 3rd quarter. Vest Financial LLC now owns 151,217 shares of the medical instruments supplier’s stock worth $45,389,000 after purchasing an additional 35,771 shares during the last quarter. Finally, Harfst & Associates Inc. lifted its holdings in West Pharmaceutical Services by 7.9% in the 3rd quarter. Harfst & Associates Inc. now owns 7,484 shares of the medical instruments supplier’s stock worth $2,246,000 after purchasing an additional 551 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST opened at $287.25 on Tuesday. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $299.96 and its two-hundred day moving average is $324.52. The company has a market cap of $20.84 billion, a P/E ratio of 40.86, a P/E/G ratio of 10.46 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business’s quarterly revenue was down 6.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.11 earnings per share. On average, equities analysts expect that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

Insider Activity

In other news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the sale, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.53% of the stock is currently owned by company insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.